Compare Lattice Semiconductor Corporation Common Stock (LSCC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lattice Semiconductor Corporation Common Stock vs Tango Therapeutics Inc. — how do they compare? Lattice Semiconductor Corporation Common Stock trades at $110.17 (market cap $16.33B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Lattice Semiconductor Corporation Common Stock is far larger — about 4.4× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (3,438,781 versus 1,986,670). Which is the better fit depends on your goals — on Pluang, investors hold Lattice Semiconductor Corporation Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| LSCC | TNGX | |
|---|---|---|
Market Cap | $16.33B | $3.74B |
Volume | 1,986,670 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $155.27 | $32.90 |
52-Week Low | $61.73 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $16.20B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lattice Semiconductor (LSCC) trades at $121.15, down 1.38% today, with a bullish technical signal from moving averages. The company shows strong revenue growth projections from $523M in 2025 to $651M in 2026, though current valuation metrics remain elevated with a P/E of 504.2. Recent news highlights leadership in AI infrastructure security and new FPGA product launches, supported by overwhelmingly positive analyst sentiment with 88% buy ratings.
LSCC presents growth potential through AI-driven semiconductor demand and expanding product portfolio, but faces risks from high valuations and competitive pressures. The consensus price target of $162.14 suggests 34% upside, though investors should monitor execution on projected margin expansion from 0.58% to 5.57% net profit margin.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Lattice Semiconductor Corporation Common Stock
Lattice Semiconductor develops low-power programmable chips, known as FPGAs. Its products are used in communications, computing, industrial, and automotive applications.
Read more on LSCC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
